Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults.

Hasan, S.S., Kow, C.S., Curley, L.E., Baines, D. and Babar, Z.U.D., 2018. Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults. Expert Review of Pharmacoeconomics and Outcomes Research, 18 (4), 371 - 377.

Full text available as:

[img] PDF (This is an Accepted Manuscript of an article published by Taylor & Francis Group in Expert Review of Pharmacoeconomics and Outcomes Research on 9/5/18)
Manuscript.pdf - Accepted Version
Restricted to Repository staff only until 9 May 2019.
Available under License Creative Commons Attribution Non-commercial No Derivatives.

136kB

DOI: 10.1080/14737167.2018.1474101

Abstract

INTRODUCTION: Anticoagulants refer to a variety of agents that inhibit one or more steps in the coagulation cascade. Generally, clinical conditions that require the prescribing of an oral anticoagulant increase in frequency with age. However, a major challenge of anticoagulation use among older patients is that this group of patients also experience the highest bleeding risk. To date, economic evaluation of prescribing of anticoagulants that includes the novel or newer oral anticoagulants (NOACs) in older adults has not been conducted and is warranted. Areas covered: A review of articles that evaluated the cost of prescribing conventional (e.g. vitamin K antagonists) and NOACs (e.g. direct thrombin inhibitors and direct factor Xa inhibitors) in older adults. Expert commentary: While the use of NOACs significantly increases the cost of the initial treatment for thromboembolic disorders, they are still considered cost-effective relative to warfarin since they offer reduced risk of intracranial haemorrhagic events. The optimum anticoagulation with warfarin can be achieved by providing specialised care; clinics managed by pharmacists have been shown to be cost-effective relative to usual care. There are suggestions that genotyping the CYP2C9 and VKORC1 genes is useful for determining a more appropriate initial dose and thereby increasing the effectiveness and safety of warfarin.

Item Type:Article
ISSN:1473-7167
Additional Information:This is an Accepted Manuscript of an article published by Taylor & Francis Group in Expert Review of Pharmacoeconomics and Outcomes Research, on 9/05/18, available online: http://www.tandfonline.com/https://www.tandfonline.com/doi/abs/10.1080/14737167.2018.1474101
Uncontrolled Keywords:Anticoagulants ; economic evaluation ; older adults ; pharmacogenetic ; warfarin ; Administration, Oral ; Age Factors ; Aged ; Anticoagulants ; Antithrombins ; Cost-Benefit Analysis ; Factor Xa Inhibitors ; Hemorrhage ; Humans ; Thromboembolism ; Warfarin
Group:Faculty of Management
ID Code:31152
Deposited By: Unnamed user with email symplectic@symplectic
Deposited On:22 Aug 2018 14:20
Last Modified:22 Aug 2018 14:20

Downloads

Downloads per month over past year

More statistics for this item...
Repository Staff Only -